# Study of Nivolumab for Advanced Cancers in India

> **NCT03444766** · PHASE4 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 100 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer (NSCLC)
- Non-Small-Cell Lung Carcinoma
- Nonsmall Cell Lung Cancer
- Kidney Cancer
- Kidney Neoplasms
- Renal Cancer
- Renal Neoplasms

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03444766
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-06
- **Primary completion:** 2019-07-17
- **Final completion:** 2019-07-17
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2020-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03444766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03444766, "Study of Nivolumab for Advanced Cancers in India". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03444766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*